Entrada Therapeutics(US:TRDA) Globenewswire·2026-02-26 12:00Core Insights - Entrada Therapeutics is advancing its clinical programs, with key data expected from ELEVATE-44-201 and ELEVATE-45-201 studies in 2026, including a positive recommendation for an increased dose in the ELEVATE-44-201 study [1][2][3] Financial Performance - As of December 31, 2025, the company reported cash, cash equivalents, and marketable securities of $295.7 million, down from $420.0 million in 2024, with a cash runway expected into Q3 2027 [7][20] - Collaboration revenue for Q4 2025 was $1.3 million, and for the full year, it was $25.4 million, a decrease from $37.4 million and $210.8 million in 2024, respectively [8] - Research and Development (R&D) expenses increased to $34.0 million for Q4 2025 and $142.3 million for the full year, compared to $33.4 million and $125.3 million in 2024 [9] - General and Administrative (G&A) expenses were $9.6 million for Q4 2025 and $41.1 million for the full year, compared to $9.9 million and $38.5 million in 2024 [10] - The net loss for Q4 2025 was $(39.2) million, and for the full year, it was $(143.8) million, compared to a net income of $1.1 million and $65.6 million in 2024 [11] Clinical Development Pipeline - Entrada is advancing multiple clinical programs for Duchenne muscular dystrophy (DMD) in the U.K., EU, and U.S., with four clinical-stage programs expected in 2026 [3] - The ELEVATE-44-201 study has completed dosing of Cohort 1, with data from this cohort expected in Q2 2026 and from Cohort 2 by year-end 2026 [3][4] - The ELEVATE-45-201 study has initiated patient dosing, with data from Cohort 1 expected in mid-2026 [3] - The company plans to submit regulatory applications for ENTR-601-50 in the EU by year-end 2026 [4] Preclinical Pipeline Expansion - Entrada has generated preclinical data for programs targeting ocular and metabolic diseases, including ENTR-801 for Usher syndrome type 2A, with a second clinical candidate expected to be announced later in 2026 [5]